View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
January 31, 2019updated 11 Jul 2022 9:55am

Merck Group granted US patent for digital-enabled supply chain security method

German-based Merck Group has been granted a patent for creating ‘crypto-objects’ based on artificial intelligence (AI) and blockchain that can be used to secure pharmaceutical supply chains.

By Allie Nawrat

German-based Merck Group has been granted a patent for creating ‘crypto-objects’ based on artificial intelligence (AI) and blockchain that can be used to secure pharmaceutical supply chains.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The patented system uses machine learning techniques to link physical objects to blockchain through unique identifiers, known as ‘fingerprints’. A range of features can be used as a fingerprint, such a chemical, DNA or image patterns.

Patent US 10,193,695 follows previous patents 10,002,302 and 10,002, 277, which also focused on securing supply chains. These include integrating physical materials in the digital world, protecting corresponding hardware and enhancing existing security functions.

Merck chief strategy officer Isabel De Paoli said: “Merck is now spearheading the development of blockchain technologies that focus on a combination of physical objects and digital security. This will have implications for all industries that depend on reliable product authenticity, such as safety-critical supply chains in the pharma and food sector.”

De Paoli continued: “This novel technology of combining physical products with blockchain will support the security interests of businesses and their products by offering them new methods of tracking their supply chain through blockchain, Internet of Things and connected workflow environments. It is also likely to eliminate inefficiencies in their existing systems.”

The new technology is being created through a project conducted at the company’s Innovative Centre, which grows ideas for viable businesses beyond Merck’s normal activities in a protected start-up environment.

This occurs in the context of an update to the EU Falsified Medicines Directive (FMD) coming into effect in mid-February. The latest FMD deadline will require mandatory validation of each pack in pharmacies and hospitals and various obligations on participants in the pharma supply chain.

Blockchain is increasingly being employed by the pharma industry to help control the growing amount of counterfeit drugs. Counterfeiting is an issue worldwide, but particularly in developing countries as regulations and technical capacity of regulators are weaker.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology